All In Biotech

Drug Trial Radar · NCT07604311

Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy

Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Dec 1, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IgA nephropathy (IgAN) is a chronic progressive kidney disease, and long-term control of proteinuria and prevention of relapse are crucial for delaying disease progression. Patients with IgAN who achieve proteinuria remission after receiving Nefecon for 9 months or longer still face the risk of proteinuria relapse after treatment discontinuation. This study is to evaluate the efficacy and safety of Nefecon 8 mg treatment for 15 months as a maintenance therapy to reduce the risk of IgAN relapse in proteinuria-remitted patients.

Conditions

  • IgA Nephropathy (IgAN)

Interventions

  • NEFECONDrug

    NEFECON 8mg once daily by mouth for 15 months

  • PlaceboDrug

    Placebo oral capsule once daily by mouth for 15 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first composite disease relapseTime frame: 15 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanfang hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.